【摘 要】
:
Objective: The signal transducer and activator of transcription–3(Stat3)mediates the expression of a variety of genes in response to cell stimuli,and thus
【机 构】
:
苏州大学药学院,苏州,江苏,215123
【出 处】
:
华东抗肿瘤药物研究新进展与肿瘤精准治疗论坛
论文部分内容阅读
Objective: The signal transducer and activator of transcription–3(Stat3)mediates the expression of a variety of genes in response to cell stimuli,and thus plays a key role in many cellular processes such as cell apoptosis and cell cycle.In addition,STAT3 is dysregulated in most tumors,such as multiple myeloma,leukemia,breast cancers,lung cancers and so on,which is closely associated with tumorigenesis.Multiple myeloma(MM)is a fetal hematological malignancy due to lack of effective drugs in the treatment of MM.This study is intendedto find novel anti-myeloma STAT3 inhibitors by a high-throughput screening and thread light on its anti-myeloma mechanism.
其他文献
Objectives: Unimolecular micelles were prepared by modification of polyamidoamine(PAMAM)dendrimersusing pluronic F68(PF68),which is expected to reverse mult
Objective: Most non-small cell lung cancer(NSCLC)patients responding to gefitinib harbor activating mu tations in the epidermal growth factor receptor(EGFR)
Background: Gastric cancer is the fourth most common cancer in the world.The development of both chemotherapy and targeted drugs are limited due to the comp
Background: β-elemene is a novel anticancer drug extracted from herb which has been used to target various solid tumours and Hyperthermia is an adjuvant th
Objective: Anti-PD-1/PD-L1 antibodies showed satisfactory efficacy in treating non-small-cell lung cancer.We conducted this meta-analysis to explore the adv
流行病学每年新增病例95.2万,死亡病例72.3万.亚洲胃癌发病率及死亡率居全世界首位.晚期胃癌的化疗进展(1)转移性弥漫型胃腺癌化疗:SP方案优于FP方案?S-1+顺铂对比5-FU+顺铂
细胞死亡程序受损被认为是慢性淋巴细胞性白血病(CLL)的显著特征之一,同时也是导致恶性单克隆B细胞大量累积以及化疗耐药的重要诱因.细胞有两种死亡途径:凋亡或坏死途径.最近
主要介绍克服酪氨酸激酶Gleevec耐药的一些进展.第一代靶点药物Gleevec耐药的主要形成机制是出现靶点点突变和基因扩增.潘景轩教授等发现了新型酪氨酸激酶抑制剂(EXEL-0862)(
AACR2015 Bert Vegelstein:靶向皆耐药 Durable tumor regression by immunotherapy ASC0 2015:Bert Vegelstein PD1单抗治疗IV期直肠癌 PD1单抗治疗肺癌:从2线到1线